What is Immunitybio Inc (IBRX) stock price today?

Immunitybio Inc (IBRX) currently trades at $6.96 per share. The stock has a market capitalization of $7.19B and a P/E ratio of —x.

Is IBRX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Immunitybio Inc has a Smart Value Score of 28/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Immunitybio Inc's revenue and earnings?

Immunitybio Inc has trailing twelve-month (TTM) revenue of $113.29M with profit margins of 0.00%. Earnings per share (EPS) is $-0.38.

IBRX

Immunitybio Inc

NASDAQ: IBRX · HEALTHCARE · BIOTECHNOLOGY

$6.96

+0.00% today

Updated 2026-04-29

Market cap

$7.19B

P/E ratio

—

P/S ratio

63.45x

EPS (TTM)

$-0.38

Dividend yield

—

52W range

$2 – $12

Volume

27.9M

Market cap

$7.19B

P/E ratio

—

P/S ratio

63.45x

EPS (TTM)

$-0.38

Dividend yield

—

52W range

$2 – $12

Volume

27.9M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.3

Growth

5.0

Quality

C+

3.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$14.80

+112.64%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 407.00% QoQ

Risks

- Thin margins at 0.00%

- Negative free cash flow $-71.25M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$240000.00	$622000.00	$14.74M	$113.29M	$113.29M
Net income	$-416.57M	$-583.20M	$-413.56M	$-351.40M	$-61.94M
EPS	—	—	—	—	$-0.38
Free cash flow	$-415.67M	$-397.34M	$-398.12M	$-308.78M	$-71.25M
Profit margin	-173,569.58%	-93,761.41%	-2,804.77%	-310.18%	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-31	SOON-SHIONG, PATRICK	Buy	4,606,596	$5.43
2026-02-24	SIMON, BARRY J.	Sale	75,000	$12.01
2026-02-23	SIMON, BARRY J.	Sale	165,000	$10.25

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
IBRX	$7.19B	28	6.3	3.0	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Immunitybio Inc trades at $6.96. Our Smart Value Score of 28/100 indicates the stock is weak. TTM revenue stands at $113.29M.

Frequently asked questions

What is Immunitybio Inc's stock price?

Immunitybio Inc (IBRX) trades at $6.96.

Is Immunitybio Inc overvalued?

Smart Value Score 28/100 (Grade F, Strong Sell).

What is the price target of Immunitybio Inc (IBRX)?

The analyst target price is $14.80, representing +112.6% upside from the current price of $6.96.

What is Immunitybio Inc's revenue?

TTM revenue is $113.29M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio63.45x

ROE—

Beta0.06

50D MA$8.19

200D MA$4.26

Shares out1.03B

Float0.38B

Short ratio—

Avg volume27.9M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

IBRX vs LLY →IBRX vs JNJ →IBRX vs ABBV →Stock screener →